Thus, the examination of β-catenin-TCF4-CEGRs/ALCDs-dependent oncogenes in a large cohort of HBL patients showed that this pathway is functioning in patients with aggressive HBL, and that the downstream targets of this pathway are elevated in HBL tumors. This evidence concerns the gene TCF4 and hepatoblastoma.